samedan logo
 
 
spacer
home > ict > autumn 2018 > clinical trials in cyberspace
PUBLICATIONS
International Clinical Trials

Clinical Trials in Cyberspace

Innovative health technologies are moving fast and have successfully found their way into clinical trials. Digital devices, wearables, sensors, and apps have the potential to serve multiple purposes in clinical research and, in an increasing number of cases, have become a central part of patientfocussed clinical trial development (1-11). A major part of the discussion around the appropriate use of technologies in clinical research, and the recommendations and guidances published by regulatory agencies and other organisations, have focussed on the use of mobile and other digital devices as unique or combination products throughout the duration of the clinical trial (12-15). However, not much (if any) attention has been paid to the potential use of these devices during the often long timeframe between the end of a trial, final regulatory approval, and broad market access.

The use of advanced technologies in healthcare have rapidly increased over the past few years, and, as a result, a growing number of patients are enrolled in clinical trials that use these technologies as part of the researched treatment or to track treatment progress. To stay abreast of these developments and be prepared for responsibility concerns arising down the road, sponsors will have to start considering what happens to the patient once the trial ends. Will patients be able to continue using these technologies or will their access be eliminated? How can clients be best transitioned to other support offerings post trial?

To become truly patient-centric, clinical trial development will need to increasingly incorporate post-trial plans for the continued use of devices, tracking mechanisms, and apps that are beneficial for patients.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Jennifer Riggins, a DIA Fellow, has extensive experience in the fields of medical affairs, medical information, medical communications, and digital capabilities. She currently serves as Advisor of Global Medical Digital Strategy and Capabilities at Eli Lilly. She has responsibility for global digital strategy development, creating and implementing impactful medical digital solutions, and understanding and shaping the external environment as it relates to medical affairs and digital. Jennifer graduated with her PharmD from Butler University College of Pharmacy, US, and has been at Eli Lilly for 25 years.

A biologist by training, Dr Sandra Blumenrath serves as science writer for DIA. Sandra brings extensive experience in scientific research, education, and communication to her role at DIA, where she produces scientific and healthcare-related content for a variety of audiences. She graduated from the University of Copenhagen, Denmark, and earned her PhD at the University of Maryland, College Park, US. Prior to joining DIA, Sandra worked as a scientist, educator, and content developer at the University of Maryland, the Howard Hughes Medical Institute, US, and the American Association for the Advancement of Science.
spacer
Dr Jennifer Riggins
spacer
spacer
spacer
Dr Sandra Blumenrath
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera organized an expert review on the present and future of inhalation products

“Connectivity in every new inhalation device?” This topic was one of those discussed with different inhalation experts - Manfred Keller, Pascal Cavaillon and Henry Chrystyn – during a round table organized by Nemera in Paris to review the advantages and limitations of inhalation devices.
More info >>

White Papers

Case Study: Getting the Client’s Trust - Oncology Program

Cmed Clinical Services

Five years ago, a biopharmaceutical company chose Cmed to conduct a phase II oncology study. Cmed’s performance of the study and the good relationship established with the Client led Cmed to be awarded a second oncology trial which a couple of years ago was followed by a third, fourth and fifth.
More info >>

 
Industry Events

Drug Delivery Partnerships 2019

28-30 January 2019, PGA National Resort & Spa in Palm Beach Gardens, FL

For 23 years, DDP has been the world’s largest drug delivery meeting place to accelerate drugs to market and lengthen lifecycles for long term profitability by finding new partners, new drug delivery technologies, and new formulation development strategies. Year after year this event brings together top scientists and business development leaders from Biotech, Pharma, Generics, Specialty Pharma and Drug Delivery companies to share, discuss, and collaborate. If you work in drug delivery, commercialization/licensing, med device, formulation, biologics, biosimilars, and similar areas, you can’t miss this event!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement